Literature DB >> 17545092

[Association of CD133 and endothelin-converting enzyme expressions with prognosis of non-small cell lung carcinoma].

Hui-zhong Zhang1, Yi-ping Wei, Mei Wang, Cheng Wu, Yan-qi Yang, Ju Chen, Yong-ke Cao.   

Abstract

OBJECTIVE: To investigate the expression of tumor stem cell marker CD133 and endothelin-converting enzymes (ECE) in non-small cell lung carcinoma (NSCLC) and their association with NSCLC lymphoid metastasis.
METHODS: CD133 and ECE expressions was detected immunohistochemically in the specimens from 77 patients with NSCLC, and the association of CD133 and ECE expressions with the tumor size, histological type, differentiation, lymphoid metastasis, and prognosis of NSCLC was analyzed.
RESULTS: The positive expression rate of CD133 and ECE was 51.9% (40/77) and 45.5% (35/77) in these specimens, respectively. Both CD133 and ECE expressions were associated positively with lymphoid metastasis (r=0.246 and 0.339, P<0.05), and inversely with the survival time of the patients (P<0.05). CD133 and ECE expressions were not related to tumor size, histological type, and differentiation of the tumor (P>0.05). CD133 expression was associated positively with ECE expression in NSCLC (r=0.249, P<0.05).
CONCLUSION: CD133 and ECE expressions are associated with lymphoid metastasis and prognosis of NSCLC, and their overexpression often suggests unfavorable prognosis of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545092

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  9 in total

Review 1.  Cancer stem cells: progress and challenges in lung cancer.

Authors:  Amanda K Templeton; Shinya Miyamoto; Anish Babu; Anupama Munshi; Rajagopal Ramesh
Journal:  Stem Cell Investig       Date:  2014-04-15

2.  Population differences in microRNA expression and biological implications.

Authors:  R Stephanie Huang; Eric R Gamazon; Dana Ziliak; Yujia Wen; Hae Kyung Im; Wei Zhang; Claudia Wing; Shiwei Duan; Wasim K Bleibel; Nancy J Cox; M Eileen Dolan
Journal:  RNA Biol       Date:  2011-07-01       Impact factor: 4.652

3.  Prognostic value of CD133 expression in stage I lung adenocarcinomas.

Authors:  Tetsukan Woo; Koji Okudela; Hideaki Mitsui; Takuya Yazawa; Nobuo Ogawa; Michihiko Tajiri; Taketsugu Yamamoto; Yasushi Rino; Hitoshi Kitamura; Munetaka Masuda
Journal:  Int J Clin Exp Pathol       Date:  2010-12-04

4.  Cancer stem cell radioresistance and enrichment: where frontline radiation therapy may fail in lung and esophageal cancers.

Authors:  Giang Huong Nguyen; Mandi M Murph; Joe Y Chang
Journal:  Cancers (Basel)       Date:  2011-03       Impact factor: 6.639

5.  CD133 expression: a potential prognostic marker for non-small cell lung cancers.

Authors:  Hidenori Mizugaki; Jun Sakakibara-Konishi; Junko Kikuchi; Jun Moriya; Kanako C Hatanaka; Eiki Kikuchi; Ichiro Kinoshita; Satoshi Oizumi; Hirotoshi Dosaka-Akita; Yoshihiro Matsuno; Masaharu Nishimura
Journal:  Int J Clin Oncol       Date:  2013-03-12       Impact factor: 3.402

Review 6.  Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review.

Authors:  Hongying Qu; Rong Li; Zhiyue Liu; Junyi Zhang; Rongcheng Luo
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

7.  The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis.

Authors:  Engeng Chen; Zhiru Zeng; Bingjun Bai; Jing Zhu; Zhangfa Song
Journal:  Oncotarget       Date:  2016-08-30

8.  Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB.

Authors:  Chun-Yan Li; Bao-Xiu Li; Yi Liang; Rui-Qing Peng; Ya Ding; Da-Zhi Xu; Xin Zhang; Zhi-Zhong Pan; De-Sen Wan; Yi-Xin Zeng; Xiao-Feng Zhu; Xiao-Shi Zhang
Journal:  J Transl Med       Date:  2009-07-07       Impact factor: 5.531

Review 9.  Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis.

Authors:  Hong Wu; Xiao-wei Qi; Guang-ning Yan; Qing-bi Zhang; Chuan Xu; Xiu-wu Bian
Journal:  PLoS One       Date:  2014-06-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.